Answers are grounded in this paper and cite their sources.
A highly efficient expression system for recombinant Escherichia coli type II L-asparaginase (EC 3.5.1.1) has been developed based on a synthetic gene optimized for the energy of secondary structure hairpins formation in the 5'-region of mRNA. A producer strain, E. coli BL21[DE3]/pET28a-AsnSYN was created, providing an accumulation of up to 291 ± 9 mg/L of enzymatically active protein (44.5 ± 2.6 mg/(L AU)) when cultivated in stirred flasks, which is 50% higher than the control strain with a natural gene at an induction time of 3 hours. Optimization of the codon composition of the gene made it possible to increase the energy of secondary mRNA structure formation in the 5'-region from –70 to –47 kcal/mol, which, as we assume, contributed to improved translation efficiency. For the developed producer strain, asparaginase that meets pharmacopoeial purity requirements can be obtained with a total yield of ≥25% and a specific activity of >250 IU/mg. The preparation contains no visible impurities according to electrophoresis data and less than 3% multimeric forms according to size exclusion chromatography data. The results obtained demonstrate the promise of using synthetic genes with optimized DNA structure for the industrial production of therapeutic enzymes.
No takes yet. Share an insight, caveat, or question.
G. R. R. Shayfutdinov (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: